AXL and sarcoma: MGCD516 is unique in a way that it has broad spectrum activity against many RTKs including c-Met, c-Kit, Axl, PDGFR, and Eph receptors that are known to play a role in driving sarcoma cell growth, and thus, it is able to inhibit many of the internal compensatory pathways.